more

Sanofi (SNY)

(Delayed Data from NSDQ)

$56.33 USD

+0.22 (0.39%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $56.32 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

Top 40% (100 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly to Bring Half-Priced Version of Popular Humalog Insulin

by Zacks Equity Research Published on March 05,2019

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

pharmaceuticals

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research Published on March 04,2019

Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.

pharmaceuticals

Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion

by Zacks Equity Research Published on March 04,2019

The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.

biotechs

Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices

by Zacks Equity Research Published on March 01,2019

Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.

pharmaceuticals

Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor

by Zacks Equity Research Published on February 26,2019

Sanofi (SNY) and partner Regeneron (REGN) disagree with a jury verdict in favor of Amgen upholding the validity of two patents related to Repatha.

biotechs

Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates

by Zacks Equity Research Published on February 22,2019

Emergent (EBS) rides high on both earnings and a revenue beat in Q4.

biotechs

BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline

by Zacks Equity Research Published on February 22,2019

BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.

biotechs

Ascendis Pharma Files IND for Hypoparathyroidism Candidate

by Zacks Equity Research Published on February 13,2019

Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.

biotechs

Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%

by Zacks Equity Research Published on February 12,2019

Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up

by Zacks Equity Research Published on February 11,2019

ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

by Zacks Equity Research Published on February 08,2019

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

pharmaceuticals

Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on February 08,2019

Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.

Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

by Zacks Equity Research Published on February 07,2019

Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

by Zacks Equity Research Published on February 06,2019

Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.

biotechs

The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA

by Zacks Equity Research Published on February 06,2019

The Zacks Analyst Blog Highlights: Pepsico, Disney, Sanofi, Diageo and HCA

medical

Top Ranked Income Stocks to Buy for February 6th

by Zacks Equity Research Published on February 06,2019

Here are three stocks with buy rank and strong income characteristics for investors to consider today, February 6th:

Can Sanofi (SNY) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research Published on February 05,2019

Sanofi (SNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

SNYPositive Net Change

Sanofi's Myeloma Candidate Meets Goal in Phase III Study

by Zacks Equity Research Published on February 05,2019

Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.